Filling the Gap on Caveolin-1 in Liver Carcinogenesis

Manuel A Fernandez-Rojo; Grant A Ramm

doi:10.1016/j.trecan.2016.10.011

Filling the Gap on Caveolin-1 in Liver Carcinogenesis

Trends Cancer. 2016 Dec;2(12):701-705. doi: 10.1016/j.trecan.2016.10.011. Epub 2016 Nov 8.

Authors

Manuel A Fernandez-Rojo¹, Grant A Ramm²

Affiliations

¹ QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia. Electronic address: Manuel.Fernandez-Rojo@qimrberghofer.edu.au.
² QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.

PMID: 28741517
DOI: 10.1016/j.trecan.2016.10.011

Abstract

Caveolin-1 (CAV1) has emerged as a promoter of proliferation, metastasis, and chemoresistance in hepatoma cells, as well as a marker of poor prognosis in liver cancer. We discuss here current knowledge and future approaches to elucidating the molecular mechanisms underlying CAV1 action during hepatocarcinogenesis and evaluate its potential use in clinical therapies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Carcinogenesis
Caveolin 1 / metabolism*
Hepatocytes / metabolism
Humans
Liver Neoplasms / drug therapy
Liver Neoplasms / metabolism
Liver Neoplasms / pathology*

Substances

Caveolin 1